Podcasts about Eli Lilly

In the past week, breakthrough developments surrounding Ozempic and its use for weight loss have dominated health news, reflecting sweeping changes in both medical access and public perception. According to Popular Mechanics, Novo Nordisk, the pharmaceutical giant behind Ozempic and the similar injectable Wegovy, has just revealed the results of a major 71-week clinical study evaluating an oral pill form of semaglutide, the active ingredient in both Ozempic and Wegovy. This study, published in The New England Journal of Medicine, found that the daily pill achieved nearly the same results as the weekly injection, with participants losing an average of 16.6 percent of their body weight, far surpassing the 2.7 percent weight loss seen in the placebo group. About one third of those taking the pill lost more than 20 percent of their starting weight, signaling not just statistical significance but profound clinical impact. The trial also reported side effects consistent with earlier injectable versions, including increased incidences of nausea and vomiting, though these were not severe enough to derail the optimism surrounding the pill's future.Compounding these scientific advancements, the White House this week announced successful negotiations with both Eli Lilly and Novo Nordisk to dramatically reduce the cost of GLP-1 receptor agonists—the drug class of Ozempic, Wegovy, and Zepbound—which many insurance providers had previously excluded or charged full price for. Now, eligible patients may see their out-of-pocket costs plummet from over one thousand dollars per month to a much more accessible fifty to three hundred fifty dollars depending on dosage and coverage. According to comments from Kim Fisher at the UC Davis Innovation Institute for Food and Health, these price adjustments are expected to drive a swift increase in demand and medication use, with around one in eight adult Americans having already tried some form of GLP-1 therapy.Despite the popularity and transformative outcomes touted by both consumers and medical professionals, Ozempic and related drugs are not without controversy. While these medications have reshaped the landscape for obesity and diabetes treatment, as UC Davis reports, emerging evidence indicates a need for caution and individualized care. Some patients experience notable gastrointestinal effects such as nausea and diarrhea, largely because GLP-1 drugs alter how the gut processes food and signal fullness to the brain. In addition, while fat loss can be dramatic, experts highlight that up to one quarter of the total weight lost may be from lean muscle, underscoring the importance of physical activity and adequate protein to preserve strength. Another concern echoed this week involves bone health, as rapid weight loss and restricted nutrition may inadvertently reduce bone density, especially in older adults and postmenopausal women. Leading researchers emphasize that a successful and safe weight loss journey with Ozempic demands precision nutrition, attentive exercise regimens, and regular monitoring to minimize health risks and maximize wellbeing.The intersection of celebrity culture with the Ozempic phenomenon also drew fresh attention over the past week, especially regarding Oprah Winfrey's evolving relationship with the drug. Oprah, who has long shared her struggles with weight publicly, admitted in recent interviews that she initially resisted taking Ozempic, saying she felt it was the easy way out and preferred to focus on lifestyle change. According to AOL, she reflected on her internal conflict about using medical intervention for weight loss, underscoring how the rise of drugs like Ozempic has forced a cultural reckoning over what constitutes effort, discipline, and legitimacy in personal health. While some celebrity peers openly dismiss rumors or deny any use of weight loss drugs, Oprah's decision to speak candidly about her hesitation and subsequent experiences gives voice to a wider conversation happening both in Hollywood and across the nation. As more public figures reveal their choices, the stigma of using medication to address chronic weight struggles may begin to dissipate, helping others seek support without shame.In summary, the past week has marked a pivotal moment in the ongoing Ozempic story. The introduction of a highly effective oral pill, substantial price cuts via government negotiation, and ongoing public debate about safety, efficacy, and cultural perceptions have all contributed to growing momentum. Now, as clinicians and patients alike look ahead to a future where advanced weight management tools are both more accessible and potentially safer to use, the importance of personalized guidance and health literacy has never been clearer.Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

California officials misled a federal judge about policies that hide students' "gender transitions" from parents at schools, bombshell documents uncovered by a legal firm appear to show.For decades, leftists in the media and in the Democrat Party have tried to sell a simple equation: to be Latino is to be liberal. They've claimed that any resistance to their radical, anti-American agenda—whether it's open borders, defunding the police, or socialist economic policies—is racist. But that narrative was never true, and millions of Latinos are proving it wrong every day. Chris Salcedo, host of the Chris Salcedo Radio Show, the Chris Salcedo Show on Newsmax TV, and The Salcedo Storm Podcast, joins me to discuss his new book, The Rise of the Liberty-Loving Latino, where he tells the story corparate, legacy media refuses to cover: how a growing number of Hispanic Americans are standing up for faith, family, freedom, and the Constitution.Last week, the White House announced new deals that Donald Trump made with drugmakers Eli Lilly and Novo Nordisk to lower the prices of some GLP-1 and weight-loss medications. J.D. Hayworth, a former House Ways and Means member and spokesperson for the Pharmaceutical Reform Alliance, joins me to discuss what this deal truly means for American patients. Is it a real step toward affordability, or just another profit play by Big Pharma? Hayworth can explain what Congress must do next to ensure lasting savings and accountability.Becky Noble, a journalist at Red State and her Substack Gumshoe Politics, joins me to discuss the latest with Chip Roy's bill to freeze immigration and the perks of working for the Chicago Public School system.Chris SalcedoThe Rise of the Liberty-Loving Latino: A New American RevolutionPharmaceutical Reform AllianceBecky Noble at Red StateGumshoe PoliticsBecome a supporter of Tapp into the Truth: https://www.spreaker.com/podcast/tapp-into-the-truth--556114/support Tapp into the Truth on Rumble. Follow, watch the older shows, and join the live streams.“Remember Pop Rocks? Now, imagine they gave you superpowers.” Please let me introduce you to Energy Rocks! Born from the grit and ambition of a competitive athlete who wanted a better, cleaner way to fuel the body and mind, without the hassle of mixing powders, messy bottles, or caffeine crashes. Energy Rocks is a reimagining of energy into something fun, functional, and fantastically effective. A delicious popping candy energy supplement that delivers a rapid boost of clean energy and focus — anytime, anywhere. No water. No mixing. No bulky bottles. Just open, pop it in your mouth, and get ready to rock. Making any time the right time to “Get in the Zone, One Pop at a Time.”Take This Free Quiz To Find Out The Best & Worst Foods To Avoid For Joint Pain!Do you wake up in the morning with stiff joints or pain in your hips, back, knees, or elbows? Then, chances are you're feeling the effects of chronic inflammation taking its toll on your body. The good news is that it is NEVER too late to help get this under control. And the best part is certain foods help you do this naturally, without the need for prescription medications.If recent events have proven anything, you need to be as prepared as possible for when things go sideways. You certainly can't count on the government for help. True liberty requires self-reliance. My Patriot SupplySupport American jobs! Support the show! Get great products at great prices! Go to My Pillow and use promo code TAPP to save! Visit Patriot Mobile or Call (817) 380-9081 to take advantage of a FREE Month of service when you switch using promo code TAPP! Morning Kick is a revolutionary new daily drink from Roundhouse Provisions that combines ultra-potent greens like spirulina and kale with probiotics, prebiotics, collagen, and even ashwagandha. Just mix with water, stir, and enjoy!Follow Tapp into the Truth on Locals Follow Tapp into the Truth on SubstackHero SoapPatriot DepotBlue CoolersKoa CoffeeBrainMDDiamond CBDSauce Bae2nd SkullEinstokBeanstoxBelle IsleMomento AIHoneyFund"Homegrown" Boone's BourbonBlackout Coffee Co.Full Circle Brewing Co.Pasmosa Sangria  

In this week’s episode of "The Top Line," we take a deep dive into the top-line performance of the biopharma industry in the third quarter. After a slow start to the year, U.S. drugmakers in particular have recovered, led by Eli Lilly. We examine which companies are hot and which are not. We also look at trends that emerged in the third quarter, such as the shortfall in vaccine sales, especially in the U.S., and companies’ sales projections for the rest of the year. Fierce Pharma’s Kevin Dunleavy and Eric Sagonowsky discuss their observations from the third quarter and put the industry’s performance in perspective compared with previous quarters. They also examine the biopharma outlook for the fourth quarter. To learn more about the topics in this episode: Q1 biopharma layoff trends, plus expectations for Q2 7 top pharmas posted revenue declines in Q1. The common thread? All are US firms Several US pharma giants stage Q2 sales turnaround after subpar results earlier in year See omnystudio.com/listener for privacy information.

The Friday Five for November 14, 2025: iPhone Pocket Brings Back… Pockets. CMS Rural Health Transformation Program Government Shutdown Update Most-Favored Nation Drug Pricing CMS GENEROUS Model   Get Connected:

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Philipp Vetter über Pfizers Abschied von Biontech, eine letzte Enttäuschung für Wirecard-Aktionäre und den Siemens-Absturz. Außerdem geht es um Tesla, Nvidia, Broadcom, Alphabet, Amazon, Cloudflare, Siemens Healthineers, Siemens Energy, Rolls-Royce, Airbus, Boeing, Volkswagen, Merck, Gilead, Johnson&Johnson, Eli Lilly, Bayer, Merck KGaA, Xtrackers MSCI World Health Care ETF (WKN: 113FD), VanEck Morningstar Developed Markets Dividend Leaders (WKN: A2JAHJ), iShares Stoxx Global Select Dividend 100 (WKN: A0F5U), Fidelity Emerging Markets Quality Income ETF (WKN: A2PQDRI), Invesco FTSE EM High Dividend Low Volatility ETF (WKN: A2AHZU) Invesco und den Euro Stoxx High Dividend Low Volatility (WKN: A2ABHF) . Hier findet ihr den BYD-Aktiensplit-Artikel von Lea: https://www.welt.de/wirtschaft/plus68a8494d5d3e123a945a783f/BYD-Aktiensplit-Was-Anleger-nach-dem-Steuer-Aerger-jetzt-wissen-muessen-und-tun-koennen.html Unter diesem Link könnt ihr euch kostenlos für die Masterclass anmelden: https://form.jotform.com/Product_Unit/masterclass-boersenweisheiten Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Fredag bliver et afgørende kapitel skrevet i dansk erhvervshistorie, når Novo Nordisk aktionærer skal vælge en stort set helt ny bestyrelse og udpege Novos nye ukronede konge, Lars Rebien Sørensen, som ny bestyrelsesleder. Allerede inden generalforsamlingen har både store udenlandske og indenlandske investorer rejst kraftig kritik af forløbet. Men hvad betyder det for Novo og Lars Rebiens muligheder som ny formand at lykkes, når store investorer allerede er kritiske, inden arbejdet går i gang? Og kan selskabet overhovedet vende skuden og konkurrere mod ærkerivalen Eli Lilly, der brøler afsted med stærke produkter og voldsom vækst? Hør debatten i denne uges udgave af Bundlinjen. Gæster: Benjamin Røpke, adm. direktør, Bahne. Gitte Lillelund Bech, ejer af LillelundBech, professionelt bestyrelsesmedlem, tidl. forsvarsminister. Søren Linding, erhvervskommentator, debatredaktør, Finans Vært: Mads Ring Producer: Kasper Søegaard.See omnystudio.com/listener for privacy information.

Synopsis: Nimbus Therapeutics CEO Abbas Kazimi walks Alok Tayi through the company's evolving pipeline and playbook for choosing the right risks in a noisy biotech environment. From Werner helicase for MSI-high cancers to a highly selective SIK2 program and GLP-1–adjacent strategies focused on body composition, Abbas details how Nimbus balances rigor, speed, and capital efficiency. He shares candid lessons from pausing and later resurrecting AMPK beta in partnership with Eli Lilly, the decision to remain modality-agnostic but small-molecule-centric, and the importance of knowing when not to chase the latest fad. Throughout, Abbas returns to a consistent theme: success at Nimbus comes from disciplined target selection, deep collaboration, and a culture that empowers teams to make hard calls in service of patients rather than headlines. Biography: Abbas Kazimi is the Chief Executive Officer of Nimbus Therapeutics. Previously, he served as Chief Business Officer, leading the company's strategic and corporate development efforts while overseeing business operations. Since joining Nimbus in 2014, he has helped raise over $630 million in equity financing and led transactions totaling more than $8 billion. Notably, Mr. Kazimi spearheaded the $6 billion sale of Nimbus's TYK2 program to Takeda, the $1.2 billion sale of its NASH (ACC) program to Gilead, and multiple licensing deals exceeding $1.5 billion with partners such as Genentech, Celgene/Roche, and Eli Lilly. Under his leadership, Nimbus has advanced four programs into the clinic, returned over $4 billion to investors, and continues to expand its computational drug discovery and clinical development capabilities. In 2025, Mr. Kazimi joined the board of Unnatural Products (UNP), a biotech company pioneering orally delivered macrocyclic peptides to tackle previously undruggable targets. He also serves on the Editorial Advisory Board for In Vivo magazine, a leading publication offering strategic insights and analysis of the pharmaceutical, biotechnology, medtech, and consumer health industries. Along with his family, he established the Kazimi Family Endowment for Data Science in Oncology at MD Anderson Cancer Center. This endowment reflects their personal commitment to philanthropy and their vision for revolutionizing cancer treatment through data-driven innovation. At the core of Mr. Kazimi's leadership is a deep sense of purpose—one that seeks to change the trajectory of medical diagnoses where options are limited. The ability to give patients, prescribers, and families a new outlook on life is a powerful responsibility—and one he knows the biopharmaceutical sector has the ability to fulfill. Before Nimbus, he was at Extera Partners, LLC (formerly PureTech Development, LLC), where he provided strategic advisory, supported fundraising, and executed numerous business development transactions. Earlier in his career, he was with JSB-Partners, LP, a specialized investment banking and advisory firm serving biotech and pharmaceutical companies. Mr. Kazimi holds a B.A. from the University of Texas at Austin and an M.S. from Harvard University.

Repræsentanternes Hus stemmer ja til budgetforslag og dermed slutter regeringsnedlukningen efter 43 dage. Vestas skærer 900 stillinger, heraf 190 i Danmark. Gregers Wedell-Wedellsborg stopper i Matas og lander topjob i Canada. Stark lider milliardtab. Eli Lilly har officielt overhalet Novo viser regnskaber. Nye fund i grønlandsk mine.Vært: Lasse Ladefoged (lasse.ladefoged@borsen.dk)

What happens when you go all in on a generic injectable that no one else wants, and it turns into a one hundred million dollar product in the first year?In this episode of Let's Combinate: Drugs + Devices, host Subhi Saadeh speaks with Usman Ahmad, former CEO of Nexus Pharmaceuticals and now CEO of Quetzal Therapeutics. Together they trace his journey from corporate finance to building a generics powerhouse with his parents, scaling a sterile injectable facility, and ultimately selling it to Eli Lilly for just under one billion dollars.They discuss the philosophy of finding the "right to win," what most companies miss about manufacturing capacity and equipment selection, how to build a team with deep industry know-how, and why Usman is now focused on bringing therapies to patients with rare diseases.This is a practical, personal, and strategic look at building something from the ground up, deciding not to sell too early, and learning how to do the hard things with intention.Topics include:-How to select the right generic molecules beyond patent expiry-Early success with isoproterenol and API sourcing-Why Nexus turned down acquisition offers-Building a commercial salesforce from scratch-Designing a facility with high speed prefilled syringe and lyo capacity-Why most other sterile sites failed-The billion dollar sale to Lilly-Launching Quetzal and developing oral arsenic for APL-The brain-eating amoeba drug and ultra rare disease strategy-Faith, confidence, and decision making under pressureTimestamps: 00:00 Introduction and Guest Welcome00:24 From Wall Street Finance to Pharma01:42 How Usman Selected Winning Generics02:58 Early Challenges Building a Generics Company05:29 Family R&D Expertise and Business Dynamics11:44 First Generic Launch and Commercial Impact16:28 Building Sterile Injectable Manufacturing Capacity18:16 Sterile Facility and Equipment Strategy22:40 Prefilled Syringe and Vial Line Capabilities23:07 Big Pharma Interest and Selling the Facility26:02 Nexus Pharma Services and the Lilly Deal27:23 Post‑Sale Reflections and New Ventures28:30 Launching Quetzal Therapeutics and Rare Disease Focus33:30 New Challenges and Confidence in Drug Development39:55 Importance of People, Teams, and Relationships41:40 Books That Shaped Usman's Thinking42:29 Where to Connect with UsmanLearn more: https://quetzaltx.comConnect with Usman: https://www.linkedin.com/in/usman-ahmed-a351b928More episodes: https://letscombinate.comUsman Ahmad is the Founder and CEO of Quetzal Therapeutics, and former CEO of Nexus Pharmaceuticals, where he led the company through explosive growth and the billion-dollar sale of its manufacturing facility to Eli Lilly. With a background in finance and a deep passion for healthcare innovation, Usman now focuses on bringing treatments to patients with rare and underserved diseases.Subhi Saadeh is a Quality Professional and host of Let's Combinate. With a background in Quality, Manufacturing Operations and R&D he's worked in Large Medical Device/Pharma organizations to support the development and launch of Hardware Devices, Disposable Devices, and Combination Products for Vaccines, Generics, and Biologics. Subhi serves currently as the International Committee Chair for the Combination Products Coalition(CPC) and as a member of ASTM Committee E55 and also served as a committee member on AAMI's Combination Products Committee.For questions, inquiries or suggestions please reach out at letscombinate.com or on the show's LinkedIn Page.

Send us a textGood morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of groundbreaking changes and innovations reshaping the landscape of drug development, clinical trials, and regulatory affairs.In a major move, Pfizer has successfully outbid Novo Nordisk to acquire Metsera for $10 billion. This strategic acquisition aims to bolster Pfizer's presence in the obesity treatment market by leveraging Metsera's GLP-1 receptor agonist technology. This acquisition underscores the continuing trend of consolidation within the pharmaceutical industry, enhancing competitive market positioning and reflecting a broader quest for novel therapeutic solutions.Eli Lilly has entered into a $1.2 billion collaboration with Sangenebio to advance RNA interference (RNAi) therapeutics targeting metabolic diseases. This partnership marks a pivotal shift towards utilizing RNAi technology to silence disease-causing genes, representing significant progress in metabolic disease treatment. The focus on innovative delivery mechanisms and targeted interventions is critical for accelerating drug development and enhancing therapeutic efficacy.Onchilles Pharma's recent Series A1 funding round, securing $25 million, marks a notable advancement in oncology therapeutics. The company's focus on dual-action cancer biologics targeting the ELANE pathway offers promising insights into immune activation in solid tumors. This investment exemplifies the growing interest in biologic therapies that provide targeted cancer treatments, potentially leading to more effective options for patients.Regulatory advancements are also making headlines. Chongqing Precision Biotech has received approval for Pujiolunxi, a treatment for pediatric relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), broadening therapeutic options for this challenging pediatric condition. Furthermore, Alembic Pharmaceuticals' generic version of Dasatinib tablets has gained FDA approval for Philadelphia chromosome-positive chronic myeloid leukemia, increasing accessibility to treatment.Several promising clinical trial results have emerged recently. Summit Therapeutics and Akeso Biopharma's Ivonescimab showed a 26% overall survival benefit in phase 3 trials for non-small-cell lung cancer. The potential of bispecific antibodies in combination therapies is gaining attention for its efficacy in difficult-to-treat cancers. Additionally, Regeneron's Dupixent has achieved phase 3 success in treating allergic fungal rhinosinusitis, reinforcing its role as a versatile treatment option across various inflammatory diseases.Advancements in cardiovascular therapeutics also continue to unfold. Merck & Co.'s Enlicitide Decanoate demonstrated over 50% LDL cholesterol reduction in a phase 3 study focused on atherosclerotic cardiovascular disease through PCSK9 inhibition. AstraZeneca's Baxdrostat showed significant blood pressure reduction in trials targeting treatment-resistant hypertension, highlighting the potential impact of aldosterone synthase inhibitors on cardiovascular health.The investment landscape remains robust with substantial fundraising activities such as Elephas Biosciences' $40 million Series B-2 for commercializing their live tumor profiling platform and Iambic's over $100 million series focused on AI-driven drug discovery. These investments underscore the industry's commitment to integrating advanced technologies like AI and live tumor profiling to enhance precision medicine capabilities.FDA regulatory updates are pivotal as well, notably with the decision to lift warning labels from hormone replacement therapy (HRT) products following an expert review that found previous warnings were based on misinformation regaSupport the show

AI and GLP-1s.As a healthcare reporter, we often get asked: ‘What are the top industry trends that brand and agency leaders are most focused on?' And that's our response: AI and GLP-1s.Luckily for you, this week's episode provides a taste of both.Our feature interview this week is an in-person conversation between managing editor Jack O'Brien and Curtis Sparrer, principal and co-founder of Bospar PR.Curtis flew in from San Francisco to preview the MM+M tracks at Haymarket Media's second annual AI Deciphered conference on Thursday. (Please note, last minute tickets are still available!)For Trends, pharma editor Lecia Bushak and editor-at-large Steve Madden get you up to speed on the week that was in GLP-1-land: from Pfizer muscling out Novo Nordisk for obesity drug developer Metsera, to the White House's drug pricing deal with Novo and Eli Lilly.Music: “Deep Reflection” by DP and Triple Scoop Music. Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, media trust, and data privacy—all under one roof. Don't wait—use promo code PODCAST for $100 off your individual ticket. Click here to register! AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket! Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

En el Consultorio de Bolsa de Capital Intereconomía, Miguel Méndez, Analista independiente, comenta su visión sobre los mercados y destaca el cambio de ánimo entre los inversores. Señala que “la semana pasada arrancamos con pánico y ahora lo hacemos con muchos índices en máximos”, reflejando la rápida recuperación del sentimiento del mercado y el impulso de los principales selectivos. En materia de commodities, Méndez pone el foco en el oro, que mantiene un comportamiento positivo. Asegura que “el movimiento alcista continúa” y añade que “para ver los 5.000 dólares habrá que esperar al año que viene”, mostrando su confianza en la fortaleza del metal precioso. También analiza el caso de la farmacéutica Eli Lilly, que considera “el claro ganador frente a Novo Nordisk”. Recomienda “dejar correr la serie al alza”, aunque advierte que conviene “mantener un stop de protección en los 918 dólares”.

One of biopharma's most memorable bidding wars finally came to an end on Friday—with Metsera right back in the arms of its original suitor, but with Pfizer paying around $10 billion for the rights to the obesity biotech, a nearly $3 billion increase over its original bid. But while Novo Nordisk may have bowed out of that race, the company still made headlines this past week, with CEO Maziar Mike Doustdar joining Eli Lilly head David Ricks at the White House on Thursday to announce a deal that will see their GLP-1 drugs offered at about $350 per month.   This marks a significant discount to the current list prices of $1086 and $1350 for Lilly's obesity drug Zepbound and Novo's comparator Wegovy, respectively. No matter how low they go, however, the GLP-1 leaders can still be undercut by compounders, Steven Grossman, policy and regulatory consultant and author of the FDA Matters blog, told BioSpace this week.   Speaking of Lilly, the Indianapolis-based pharma had a busy week, reporting 20% weight loss in a mid-stage study of its amylin agonist eloralintide that William Blair analysts said “validates [the] amylin agonist class.” Lilly also netted two new partners, inking a $1.2 billion RNAi pact with SangeneBio to target metabolic diseases and licensing a genetic eye disease therapy from MeiraGTx Holdings for up to $475 million.   On the regulatory front, the FDA awarded the second round of priority review vouchers under its new Commissioner's National Priority Vouchers program. Unlike the first cohort of vouchers, which was announced in October, this group mostly consisted of products already on the market—with the exception of Lilly's orforglipron.   Finally, BioSpace dives into one the hottest trends in the immunology and inflammation (I&I) space—pipeline-in-a-product. Possibly motivated by blockbuster drugs like AbbVie's Skyrizi and Rinvoq and Regeneron and Sanofi's Dupixent, companies are optimizing shots on multiple goals in this lucrative space.  

Timestamps:6:03 – Breakdown of FICO15:15 – Futures Trading Tip of the Week18:37 – Trump's $2K Tariff Plan34:46 – Burry's Shorts on NVDA & Palantir46:00 – What to Do After Becoming a Millionaire59:00 – Is Google the Sleeper AI Giant?1:04:10 – Holiday Market Play: Crypto or Stocks?1:08:20 – Trump x NVO x LLY Partnership Breakdown1:15:46 – Pre-Recession Indicators to Watch1:24:53 – CMG vs. CAVA Investment Outlook1:28:20 – End of Government Shutdown1:32:00 – Key Market Indicators for 20271:33:22 – Weekly Earnings RecapIn this week's Market Mondays, we break down everything from Trump's $2,000 plan to the future of AI and the latest market indicators signaling what's ahead for investors.We start with a deep dive into FICO scores and how they impact your financial future, then move into futures trading tips and Trump's bold plan to give every American $2,000 from tariff profits.We also discuss Michael Burry's short positions against Nvidia and Palantir, whether Google is the sleeper giant in AI, and what to do after you become a millionaire.Plus — we analyze Trump's new partnership with Novo Nordisk and Eli Lilly, what it means for biotech investors, and which markets — crypto or stocks — to focus on during the holiday season.As the government shutdown ends, we reveal key pre-recession indicators to watch, whether Chipotle (CMG) or CAVA are smart plays right now, and what signals could define the path to 2027.#MarketMondays #EarnYourLeisure #Investing #StockMarket #Crypto #FuturesTrading #TrumpEconomy #AIStocks #NVDA #Google #Palantir #NVO #LLY #FinancialEducation #WealthBuilding #RecessionPrep #EYLOur Sponsors:* Check out PNC Bank: https://www.pnc.com* Check out Square: https://square.com/go/eylSupport this podcast at — https://redcircle.com/marketmondays/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

[00:07:23] – The Black Committee: America's First Mass Surveillance ProgramBeito explains Senator Hugo Black's seizure of millions of private telegrams to spy on FDR's opponents — a little-known episode that prefigured today's surveillance state and “national security” abuses. [00:27:29] – The Newport Sex Scandal and FDR's Moral HypocrisyKnight and Beito expose Roosevelt's secret Navy operation that used entrapment to target suspected homosexual sailors — a scandal later erased from mainstream history. [00:39:31] – Going Off Gold: Roosevelt's Monetary RevolutionThe discussion covers how FDR's abandonment of the gold standard and arbitrary price-fixing launched America's age of fiat currency, inflation, and centralized economic manipulation. [00:49:16] – The “Fake News” Law That Almost HappenedBeito recounts a 1930s proposal to criminalize “false news” under FDR's influence — an early prototype of modern truth policing and digital censorship laws. [01:00:16] – The 72-Dose Childhood Vaccine LawsuitKnight reviews a lawsuit claiming the CDC never tested the combined safety of its full childhood vaccine schedule, arguing the agency hides behind untested assumptions of safety. [01:14:46] – Eli Lilly Bribery and Big Pharma CorruptionKnight reports on a Texas lawsuit accusing Eli Lilly of paying doctors to push high-profit drugs, tying it to systemic collusion between pharmaceutical giants and captured regulators. [01:24:23] – James Bradley on Vietnam: Precious FreedomAuthor James Bradley joins to discuss his book Precious Freedom, reframing the Vietnam War from the Vietnamese perspective and exposing decades of U.S. and media propaganda. [01:36:39] – Media Lies and CIA MythsBradley reveals how the U.S. and its allies fabricated the idea of “North and South Vietnam” as separate nations, a CIA-backed myth used to justify decades of warfare. [02:22:00] – Fourth Turning Politics and the Rise of Authoritarian SaviorsKnight and Bonta examine how historical cycles of crisis create conditions for strongmen like FDR, Trump, and others who exploit social chaos to centralize power. [03:02:17] – De-Dollarization and the End of U.S. Financial SupremacyBonta closes by warning that the weaponization of the dollar is accelerating the global shift toward BRICS and gold-backed trade systems, threatening the foundation of American economic dominance. Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

With ObesityWeek yielding eye-catching amylin data and a bidding war that ran to $10 billion for Metsera, weight loss companies were center stage in biotech last week. On the latest edition of the BioCentury This Week podcast, BioCentury's analysts explained why Pfizer's victory for the start-up over European rival Novo Nordisk doesn't necessarily mean a broader U.S. policy shift against foreign acquisitions of domestic biotechs.Turning to ObesityWeek readouts, they discuss Eli Lilly's data for amylin monotherapy eloralintide, arguing that just as Lilly did with GLP-1 agonists, the company is again setting the benchmark by which all other molecules in the class will be measured.BioCentury's analysts also discuss takeaways from Washington Editor Steve Usdin's Commentary, which finds FDA in a crisis of politicized decisions, plummeting morale, and a hollowed workforce, and highlights from BioCentury's interview with gene therapy pioneer Jim Wilson as he rethinks the funding model for ultrarare disease therapies to keep his mission on track. This episode of the BioCentury This Week podcast is brought to you by Voyager Therapeutics.View full story: https://www.biocentury.com/article/657545#ObesityWeek #Amylin #GLP1 #Eloralintide #DrugMechanism #FDA #RareDisease #GeneTherapy00:01 - Sponsor Message: Voyager Therapeutics 01:53 - Pfizer Wins Metsera08:48 - Lilly's Amylin Data13:06 - Funding Ultrarare Therapies20:51 - What's Next for FDATo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Ken Shreve and Ed Carson analyze Tuesday's market action and discuss key stocks to watch on Stock Market Today. Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In today's rapidly evolving landscape, we witness significant strides shaping the future of drug development, patient care, and global market dynamics.Merck & Co. has made a notable advancement in cholesterol management with a PCSK9-targeted pill. This pill has achieved reductions in low-density lipoprotein cholesterol (LDL-C) comparable to existing injectable therapies. Such innovation represents a significant step forward by potentially offering a more convenient oral alternative for patients. The development underscores the industry's ongoing efforts to enhance patient compliance and therapeutic outcomes through novel drug delivery mechanisms.In a strategic corporate move, Pfizer has successfully acquired Metsera, an obesity biotech company, for a substantial $10 billion. This acquisition, which followed an intense bidding war with Novo Nordisk, exemplifies Pfizer's aggressive expansion in the obesity treatment market—a growing global health challenge. The strategic buyout positions Pfizer to leverage Metsera's expertise, potentially accelerating the development and commercialization of innovative obesity treatments.Meanwhile, Novo Nordisk is enhancing its presence in India by partnering with Emcure Pharmaceuticals to expand access to Wegovy, its weight-loss treatment. This collaboration is particularly significant given India's escalating obesity rates and highlights the importance of regional partnerships in enhancing drug accessibility and addressing public health issues.Regulatory developments continue to influence industry dynamics as well. The FDA has postponed its decision on expanding Rhythm Pharmaceuticals' Imcivree for additional indications. These regulatory delays highlight the complexities and unpredictabilities inherent in drug approval processes, underscoring the need for companies to strategically navigate these challenges.Regeneron and AstraZeneca have reported clinical trial successes with their respective anti-inflammatory drugs, Dupixent and Fasenra. These positive outcomes were showcased at the American College of Allergy, Asthma, and Immunology's annual meeting, bolstering the companies' aspirations for FDA approvals. Successful clinical outcomes not only pave the way for expanded therapeutic options but also demonstrate the industry's commitment to addressing complex inflammatory conditions.October has seen a surge in TV advertising spending, led by Johnson & Johnson's campaign for Tremfya. The campaign highlights the power of patient community engagement in bringing attention to conditions like inflammatory bowel disease (IBD), emphasizing how patient advocacy can reduce isolation among sufferers.In oncology, Cogent Biosciences is on track for an FDA submission following successful phase 3 trials of its cancer asset bezuclastinib. This development illustrates the critical role of rigorous clinical research in advancing oncology treatments and potentially improving patient outcomes.Turning our attention to technological frontiers within pharmaceutical R&D, Eli Lilly has been particularly active in cementing its commitment to artificial intelligence (AI) and gene therapy through several strategic collaborations. The company has entered into a $100 million-plus research agreement with Insilico Medicine to leverage AI for drug discovery. This partnership aims to expedite the identification of novel therapeutic targets and enhance drug development efficiency—a reflection of a broader industry trend towards integrating AI into pharmaceutical processes.Additionally, Lilly has made a notable move in gene therapy by acquiring rights from MeiraGTx for a retinal disease therapy that has shown Support the show

In this powerful episode, I will break down one of the biggest developments in obesity and diabetes treatment in U.S. history. Two major pharmaceutical companies - Eli Lilly and Novo Nordisk - have reached a groundbreaking agreement with the administration that will drastically reduce the prices of popular medications like Wegovy, Ozempic, and Zepbound. This pricing model could transform how obesity medications are covered, distributed, and accessed across Medicare, Medicaid, and direct-to-consumer platforms. Tune in to learn what this new deal means for patients, healthcare providers, and public health overall—and why it's being called a game changer for people struggling with obesity and related health conditions. Episode Highlights: Major price cuts announced for Wegovy, Ozempic, and Zepbound under a new federal deal   Medicare to cover obesity drugs for the first time through a five-year pilot program   Medicaid given the option to join discounted pricing starting 2026   Team Rx launches a direct-to-consumer model cutting out costly middlemen   Lower cash prices for GLP-1 medications and upcoming oral versions   Eli Lilly and Novo Nordisk to invest billions in U.S. manufacturing   Program expected to improve access, affordability, and supply of obesity and diabetes meds   Ongoing push for the Treat and Reduce Obesity Act to expand national coverage   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''. Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Philipp Vetter über wacklige KI-Börsen, den neuen Plan für Siemens Healthineers und was diese Woche sonst noch wichtig wird. Außerdem geht es um Palantir, Nvidia, Meta, Microsoft, ASML, SAP, Infineon, Volkswagen, Siemens, Altair, Rumble, Northern Data, Merck & Co., Amgen, Regeneron Pharmaceuticals, Sanofi, AstraZeneca, Novo Nordisk, Eli Lilly, Robinhood und Walmart. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of groundbreaking developments that are reshaping the landscape of drug development and patient care. These stories highlight the dynamic nature of the pharmaceutical and biotechnology industries, where scientific advancements and regulatory changes are driving significant shifts.We begin with a crucial milestone in oncology treatment. The FDA has granted approval to Johnson & Johnson's Darzalex Faspro for patients with high-risk smoldering multiple myeloma. This approval is particularly significant as it provides a new therapeutic pathway for individuals with this precursor condition to active multiple myeloma, which previously had few treatment options. The drug works by targeting CD38 proteins on myeloma cells, representing a leap forward in monoclonal antibody treatments for cancer. This decision underscores the FDA's ongoing commitment to expanding treatment options for conditions with high unmet needs, potentially setting a precedent for future approvals in early-stage malignancies.Meanwhile, Gilead Sciences encountered challenges with its oncology pipeline as Trodelvy failed to meet its primary endpoint in a Phase 3 trial for first-line HR+/HER2-negative metastatic breast cancer. This outcome highlights the complexities of oncology drug development, despite previous successes in other indications. Such setbacks remind us of the inherent risks involved in bringing innovative therapies to market.In contrast, Akeso has announced positive data for ivonescimab, a PD-(L)1xVEGF bispecific antibody. The drug demonstrated significant overall survival benefits in patients with previously treated EGFR-mutated non-small cell lung cancer. This advancement underscores the therapeutic potential of bispecific antibodies in cancer immunotherapy, which continue to gain traction as they target multiple pathways involved in tumor growth and immune evasion.Regulatory incentives have also been making waves. The FDA's rollout of the second round of "national priority" voucher winners aims to accelerate drug development timelines, particularly in critical areas such as obesity. Companies like Lilly and Novo Nordisk have been recognized for their efforts, highlighting a broader strategy to bring transformative therapies to market more swiftly.On the corporate front, Bayer's proposed private equity buyout fell through due to insufficient shareholder support, reflecting ongoing financial volatility and strategic recalibrations within biotech firms. Meanwhile, CMS's introduction of a new Medicaid pricing model aims to implement "most-favored nation" pricing strategies to control drug costs, signaling potential shifts in how pharmaceutical companies approach pricing negotiations and reimbursement strategies.Technological advancements are also at the forefront of innovation. Eli Lilly has expanded its AI-driven drug discovery partnership with XtalPi, focusing on antibody development. This collaboration exemplifies how AI is increasingly being integrated into pharmaceutical research to enhance drug discovery processes.Furthermore, China's decision to lift its ban on Illumina's DNA sequencers is expected to facilitate greater access to advanced genomic technologies within the region, fostering innovation in precision medicine.Leadership changes continue to shape industry dynamics. For instance, Recursion Pharmaceuticals is undergoing executive restructuring to better align with evolving market needs and innovation strategies. These changes are crucial for maintaining competitiveness and fostering an environment conducive to scientific breakthroughs.The industry is also witnessing strategic realignmenSupport the show

In Part 1 we looked at an early study of GLP1 drugs and muscle loss. Today we'll look at two more recent studies, one for Eli Lilly's drug tirzepatide and one for Novo Nordisk's drug semaglutide. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

Three more suspects, including two affluent New Jersey teens, are now charged in a foiled ISIS-inspired Halloween terror plot, bringing the total to five. The FAA is cutting up to 10% of flights at 40 major airports as the government shutdown enters week six, triggering nationwide delays. President Trump announces a deal with Eli Lilly and Novo Nordisk to slash the cost of popular GLP-1 weight-loss drugs like Wegovy and Ozempic to about $350 through a new program called TrumpRX. Former House Speaker Nancy Pelosi, 85, announces she will not seek reelection after nearly four decades in Congress and two impeachments of President Trump. Geviti: Go to https://gogeviti.com/megynand get 20% off with code MEGYN. Walmart: Learn how Walmart is fueling the future of U.S. manufacturing at https://Walmart.com/America-at-work Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Today's Headlines: House Democrats want no-longer-Prince Andrew to testify about his ties to Jeffrey Epstein. Meanwhile, Nancy Pelosi announced her retirement, with California Sen. Scott Wiener emerging as the establishment pick — though AOC's ex–campaign manager Saikat Chakrabarti plans to run too. A federal judge ruled again that Trump must fully fund SNAP benefits by today, but the DOJ is appealing. Trump also struck a deal with Eli Lilly and Novo Nordisk to cap Ozempic-style drugs at $50 for Medicare and Medicaid patients next year. In smaller but iconic justice news, the D.C. “sandwich guy” who threw a sub at an ICE agent was found not guilty of assault. The Heritage Foundation is in “open revolt” after its president defended Tucker Carlson for hosting white supremacist Nick Fuentes. Staffers, including members of its antisemitism task force, have quit. Meanwhile, FIFA announced a mysterious new “peace prize” ahead of the World Cup draw in D.C., which insiders say Trump demanded after missing out on a Nobel. And Tesla's board is set to hand Elon Musk a $1 trillion compensation deal. Resources/Articles mentioned in this episode: Politico: House Oversight Democrats call on embattled royal Andrew Windsor to testify - Live Updates Politico: California's attorney general endorses Scott Wiener to succeed Pelosi NYT: Judge Orders Trump Administration to Fully Fund SNAP Benefits This Month WaPo: Trump, long fixated on ‘fat drug,' announces deal to lower its price WaPo: Jury finds D.C. ‘sandwich guy' not guilty of assaulting officer WaPo: Heritage staff in open revolt over leader's defense of Tucker Carlson Axios: Trump teased as possible first FIFA Peace Prize winner CNBC: Elon Musk expected to prevail in Tesla shareholder vote over CEO's $1 trillion pay plan  Morning Announcements is produced by Sami Sage and edited by Grace Hernandez-Johnson Learn more about your ad choices. Visit megaphone.fm/adchoices

The White House has struck a deal with two more drugmakers: Eli Lilly and Novo Nordisk. Centers for Medicare and Medicaid Services administrator Dr. Mehmet Oz discusses the administration's plan to make GLP-1s more affordable for Americans. Tesla shareholders voted to approve Elon Musk's $1 trillion pay package, as long as he reaches their lofty goals for the company. Musk biographer Walter Isaacson discusses the plan of milestones and Musk's history of exceeding investor expectations. Plus, U.S. airlines are beginning to cancel flights to manage shutdown-strained staffing of air traffic controllers, and Warren Buffett issued a warning on AI.  Dr. Mehmet Oz - 21:43Walter Isaacson - 38:56 In this episode:Dr. Mehmet Oz, @DrOzJoe Kernen, @JoeSquawk Andrew Ross Sorkin, @andrewrsorkinKatie Kramer, @Kramer_Katie Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Tesla shareholders put Elon Musk on the path to becoming a trillionaire. Meta is earning a fortune from fraudulent ads – host Carmel Crimmins discusses our exclusive. Reuters also reveals Google's plan to build an AI centre on a tiny Australian Indian Ocean island. And Novo Nordisk and Eli Lilly cut a deal with Trump to slash weight-loss drug prices.     Sign up for the Reuters Econ World newsletter here. Listen to the Reuters Econ World podcast here. Find the Recommended Read here. Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt out of targeted advertising. Learn more about your ad choices. Visit megaphone.fm/adchoices

Ny prisaftale om vægttabsmedicin med Novo Nordisk og Eli Lilly. Den fortsatte budkrig mellem Novo og Pfizer. Bavarian Nordics fremtid på børsen er sikret for nu. Danske regnskaber. DFDS skærer til. Gigantisk lønpakke til Elon Musk. Vært: Trine Duvander (trine.duvander@borsen.dk)

Mehr Infos zum Kreditangebot von unserem Partner Scalable Capital findet ihr hier: https://de.scalable.capital/credit. Zalando und DHL liefern, Börse jubelt. Datadog überzeugt. Eli Lilly und Novo Nordisk haben Deal mit Trump. Duolingo will wachsen und nicht profitabel werden, Börse schimpft. Marvell wurde fast gekauft, HelloFresh hat Short-Attacke und Take-Two verschiebt GTA VI wieder. Lemonade (WKN: A2P7Z1) will das OpenAI der Versicherungswelt werden. Klappt das? Quantencomputing-Aktien waren an der Börse in den letzten Monaten Highflyer. Wie funktioniert die Technologie, wie funktioniert der Markt und wie erkennt man vertrauensvolle Firmen? Daniel Volz von Kipu Quantum klärt auf. Diesen Podcast vom 07.11.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

En Capital Intereconomía hemos seguido en directo la apertura del Ibex 35 y del resto de bolsas europeas, que arrancan la jornada con volatilidad y caídas moderadas arrastradas por el nuevo golpe al sector tecnológico y las dudas sobre el empleo en Estados Unidos. En el análisis de los mercados, Xavier Brun, responsable de renta variable europea en Trea AM, explicó que el tono negativo de las bolsas viene marcado por la corrección de las compañías de inteligencia artificial y el informe de la consultora privada ADP, que apunta a un recorte de empleo en octubre, lo que incrementa la incertidumbre sobre la fortaleza económica norteamericana. Brun también señaló que la batalla tecnológica entre EE.UU. y China sigue afectando al sentimiento inversor: las exportaciones chinas vuelven a caer, lastradas por la menor demanda estadounidense, y el bloqueo de chips de IA agrava la tensión entre ambos países. Al mismo tiempo, los mercados descuentan una bajada de tipos por parte de la Fed tras los últimos datos secundarios de empleo, aunque el presidente de la Fed de Chicago, Austan Goolsbee, ha advertido sobre el “oscurantismo de la inflación” y la necesidad de mantener la prudencia monetaria. En el plano empresarial, el sector farmacéutico fue protagonista después de que Eli Lilly y Novo Nordisk alcanzaran un acuerdo con la Administración Trump para reducir los precios de sus fármacos contra la obesidad, un movimiento que busca aliviar la presión política sobre el coste de los medicamentos y estabilizar el mercado sanitario. La jornada concluye con el consultorio de bolsa junto a Javier Alfayate, gestor de fondos, que respondió a las dudas de los oyentes sobre oportunidades en renta variable en un contexto de alta rotación sectorial y creciente nerviosismo en los mercados.

La Administración Federal de Aviación de EEUU ordena una reducción del 4% en los vuelos previstos para hoy. El presidente de EEUU, Donald Trump, acuerda con Eli Lilly y Novo Nordisk bajar el precio de medicamentos para perder peso. El bloqueo de Junts a la legislatura paralizará, además de los PGE, nueve leyes en materia económica

From Singapore’s banking results to Elon Musk’s trillion-dollar payday - markets are buzzing with big money moves. Singapore’s three big banks - DBS, OCBC, and UOB - are showing their hand this earnings season, revealing who’s playing defense and who’s cashing in. Michelle Martin breaks down the numbers behind OCBC’s steady profits and DBS’s record highs, plus UOB’s caution. Across the Pacific, Trump’s deal with Eli Lilly and Novo Nordisk could reshape the obesity drug market. And Tesla’s US$1 trillion pay plan for Elon Musk? It’s the governance story investors can’t ignore. Plus, a quick game of Up or Down featuring Genting Singapore, SingTel, CapitaLand Investment, and SGX.See omnystudio.com/listener for privacy information.

Millions of Americans will soon have direct access to popular weight-loss drugs at far lower prices than they pay now. That’s due to a deal announced between President Trump and pharmaceutical giants Eli Lilly and Novo Nordisk. William Brangham discussed the deal and its potential impact with Stacie Dusetzina of Vanderbilt University. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

Gear up, freedom fighters—@intheMatrixxx and @shadygrooove charge into Season 7, Episode 212, "Trump Makes Announcement; Erika Kirk 1st Interview," dismantling deep-state distractions while spotlighting President Trump's powerhouse move to slash obesity drug prices to $149 a month for many Americans through deals with Eli Lilly and Novo Nordisk. As relentless exposers of globalist schemes, the hosts dissect this win for everyday patriots against Big Pharma greed, then pivot to Erika Kirk's raw, faith-fueled first TV sit-down since her husband Charlie Kirk's tragic assassination, where she honors his Turning Point USA legacy and stands firm amid loss. With sharp live breakdowns and unyielding America-First analysis, they equip you to reject establishment spin and defend sovereignty. The truth is learned, never told—the constitution is your weapon. Tune in at noon-0-five Eastern LIVE to stand with Trump! Trump, drug prices, Erika Kirk, Charlie Kirk, America First, MG Show, @intheMatrixxx, @shadygrooove, Turning Point USA, Big Pharma, patriotic intel mgshow_s7e212_trump_makes_announcement_erika_kirk_1st_interview Tune in weekdays at 12pm ET / 9am PST, hosted by @InTheMatrixxx and @Shadygrooove. Catch up on-demand on https://rumble.com/mgshow or via your favorite podcast platform. Where to Watch & Listen Live on https://rumble.com/mgshow https://mgshow.link/redstate X: https://x.com/inthematrixxx Backup: https://kick.com/mgshow PODCASTS: Available on PodBean, Apple, Pandora, and Amazon Music. Search for "MG Show" to listen. Engage with Us Join the conversation on https://t.me/mgshowchannel and participate in live voice chats at https://t.me/MGShow. Social Follow us on X: @intheMatrixxx https://x.com/inthematrixxx @ShadyGrooove https://x.com/shadygrooove Follow us on YouTube: ShadyGrooove https://www.youtube.com/c/TruthForFreedom Support the show: Fundraiser: https://givesendgo.com/helpmgshow Donate: https://mg.show/support Merch: https://merch.mg.show MyPillow Special: Use code MGSHOW at https://mypillow.com/mgshow for savings! Wanna send crypto? Bitcoin: bc1qtl2mftxzv8cxnzenmpav6t72a95yudtkq9dsuf Ethereum: 0xA11f0d2A68193cC57FAF9787F6Db1d3c98cf0b4D ADA: addr1q9z3urhje7jp2g85m3d4avfegrxapdhp726qpcf7czekeuayrlwx4lrzcfxzvupnlqqjjfl0rw08z0fmgzdk7z4zzgnqujqzsf XLM: GAWJ55N3QFYPFA2IC6HBEQ3OTGJGDG6OMY6RHP4ZIDFJLQPEUS5RAMO7 LTC: ltc1qapwe55ljayyav8hgg2f9dx2y0dxy73u0tya0pu All Links Find everything on https://linktr.ee/mgshow Intermission Music Lemurian Shores (with Lucentia) (~432 Hz) by Spheriá | https://soundcloud.com/spheriamusic Music promoted by https://www.chosic.com/free-music/all/ Creative Commons CC BY-SA 3.0 https://creativecommons.org/licenses/by-sa/3.0/

A federal judge ruled Thursday that the Trump administration must fully fund SNAP benefits amid the government shutdown, giving officials until Friday to secure the money. Meanwhile, as the shutdown continues, 40 major U.S. airports—including Los Angeles International, John F. Kennedy International, and Chicago O'Hare—will face a 10 percent reduction in flights starting Friday.President Donald Trump, just one day after Supreme Court arguments on his sweeping global tariffs in a case he called “one of the most important cases in the history of our country,” is doubling down—emphasizing that his tariff threats against Beijing were a national security lifeline that forced Xi Jinping to the negotiating table. The president is also set to meet with the leaders of all five Central Asian countries Thursday night as the United States works to expand its influence in a region increasingly courted by China.Trump also announced new agreements to expand access to and reduce the cost of weight loss drugs. The deals with pharmaceutical companies Novo Nordisk and Eli Lilly will broaden coverage for Medicare and Medicaid recipients and lower the prices paid by the federal government.

Millions of Americans will soon have direct access to popular weight-loss drugs at far lower prices than they pay now. That’s due to a deal announced between President Trump and pharmaceutical giants Eli Lilly and Novo Nordisk. William Brangham discussed the deal and its potential impact with Stacie Dusetzina of Vanderbilt University. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

President Trump strikes a groundbreaking deal with Eli Lilly and Novo Nordisk to slash prices on popular weight-loss drugs for Medicare, Medicaid, and out-of-pocket patients. Nov 6th 2025 --- Please Like, Comment and Follow 'The Ray Appleton Show' on all platforms: --- 'The Ray Appleton Show’ is available on the KMJNOW app, Apple Podcasts, Spotify, YouTube or wherever else you listen to podcasts. --- 'The Ray Appleton Show’ Weekdays 11 AM -2 PM Pacific on News/Talk 580 AM & 105.9 KMJ | Website | Facebook | Podcast | - Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

President Donald Trump announced a major initiative aimed at lowering the cost of popular weight loss drugs in the U.S. Pres. Trump unveiled deals with Eli Lilly and Novo Nordisk to reduce prices on Wegovy (Novo Nordisk), Zepbound (Eli Lilly) and potential inclusion of Ozempic, primarily a diabetes drug also used for weight loss. Please Like, Comment and Follow 'Broeske & Musson' on all platforms: --- The ‘Broeske & Musson Podcast’ is available on the KMJNOW app, Apple Podcasts, Spotify or wherever else you listen to podcasts. --- ‘Broeske & Musson' Weekdays 9-11 AM Pacific on News/Talk 580 AM & 105.9 FM KMJ | Facebook | Podcast| X | - Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

Earnings are filtering in, and companies are seeing a tale of two very different consumers. The group raising concerns about their customer base, and the names not seeing any slowdown. Plus Novo and Eli Lilly nearing a deal with the White house to lower obesity drug prices. What it means for the space, and how it could change medicare coverage of the weight loss drugs.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

New York's mayor-elect, Zohran Mamdani, is promising to tackle the city's soaring cost of living. Ed Butler looks at what his victory could mean for businesses.Also, Eli Lilly and Novo Nordisk agree to slash the cost of blockbuster weight-loss drugs like Ozempic and Wegovy under a new Medicare deal. And why Shein is facing a backlash in France.

Listen to Daily Global #News from Grecian Echoes WNTN 1550 AM -  Democrats won the races in the first major elections since Trump became president - Trump is negotiating a deal with Eli Lilly and Novo Nordisk that would lower obesity drug price - The government shutdown has entered its 36th day, setting a new record

Bonus Episode for Nov. 4. The weight-loss-drug arms race is only heating up, as Novo Nordisk attempts to snatch drugmaker Metsera away from Pfizer. But can either company compete with Zepbound seller Eli Lilly? WSJ reporter Peter Loftus discusses what earnings from Big Pharma, including AbbVie, Bristol Myers Squibb and Merck, say about the future of the industry and how companies are responding to President Trump's drug-pricing plans, including TrumpRx. WSJ Heard on the Street columnist David Wainer hosts this special bonus episode of What's News in Earnings, where we dig into companies' earnings reports and analyst calls to find out what's going on under the hood of the American economy. Sign up for the WSJ's free Markets A.M. newsletter. Further Reading: Novo Nordisk Sweetens Offer for Metsera - WSJ Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal Why Pfizer Can Still Prevail in the Obesity Fight With Novo Nordisk The Day Pharma's Weight-Loss Gold Rush Intensified Pfizer Profit Falls Amid Lower Covid-19 Drug Demand Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera Novo Nordisk to Shake Up Board After Obesity-Market Challenges Mounjaro Powers Eli Lilly to Bumper Quarter of Earnings AbbVie Lifts Profit Outlook as Sales Rise Bristol Myers Squibb Profit Soars, Raises Revenue Guidance Merck Profit Rises on Strong Keytruda Demand GSK Lifts Guidance After Specialty Medicines Boost Sales Novartis Expects to Ride Out Patent Losses With Sales, Profit Growth Ahead Biogen Cuts Full-Year Earnings Guidance, Despite Third-Quarter Profit Rise J&J Lifts Full-Year Sales Outlook, Fueled by Pharma, Med-Device Gains Learn more about your ad choices. Visit megaphone.fm/adchoices

On this episode of The Medical Alley Podcast, we're recognizing Alzheimer's Awareness Month with three special guests: Dr. Brandy Matthews (VP, Global & US Medical Affairs, Alzheimer's Disease at Eli Lilly and Company), Dr. Ronald Petersen (Neurologist, Mayo Clinic Alzheimer's Disease Research Center), and Robert Freeman (VP, Public Policy, Alzheimer's Association, MN-ND Chapter).In the discussion, we break down what Alzheimer's Disease is, how it's diagnosed, the latest innovations in research and treatments, and what the future of Alzheimer's care could look like.Send us a message! Follow Medical Alley on social media on LinkedIn, Facebook, X and Instagram.

Dave and Brandon cover more of the winners and losers from the Q3 2025 earnings season

En el episodio de hoy, analizamos cómo prevaleció el Team Alcaldes en el más reciente pulso político entre la Gobernadora y la Legislatura. En el segundo bloque, abordamos la expansión histórica de Eli Lilly en Puerto Rico, una inversión multimillonaria que el gobierno celebra como una gran victoria económica. Más adelante, conversamos sobre Trump, el filibusterismo y la estadidad, en medio del cierre del gobierno federal y la creciente incertidumbre política en Washington. Y para cerrar, un Patreon Exclusive con la designación de Josué Rivera al Banco de Desarrollo Económico — una movida que da mucho de qué hablar. En el chit chat discutimos el rant viral de Carlitos Bermúdez, la respuesta de Pablo José, y todo el contenido del fin de semana: Halloween, K-Pop Demons Hunters, Blippi, el velociraptor y el unicornio más viral del mes. Octubre cierra caliente y viene noviembre, el mejor mes para entrar al Patreon — con preventa y descuentos exclusivos de los PPP Awards. Si fueras integrante de nuestro Patreon, hubieras escuchado este episodio ayer. Únete ahora en patreon.com/puestospalproblema! Presentado por AeroNet – Nuevo plan GigaFaster Essential: 200/50 Mbps por $99 al mes, con router WiFi incluido.

Christine Short and Scott Zari cover Eli Lilly (LLY) earnings and the future of GLP-1 drugs. Christine emphasizes the global demand for these drugs, as evidenced by higher international revenue, and what a daily oral GLP-1 pill could do for the company. Scott looks at Eli Lilly's market share in the weight loss sector, calling it a “two horse race” between them and Novo Nordisk (NVO).======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

1. Sigue el “excelente ambiente laboral” dentro del PNP. Del impuesto al inventario a la reforma contributiva. TRS vuelve al ataque. 2. Nuevas señales de crisis financiera de New Fortress. Busca mecanismo similar a la quiebra en Inglaterra 3. Vista pública ayer en la Cámara no contestó las interrogantes sobre la crisis de liquidez financiera del sistema eléctrico 4. Gobernadora dice hay hasta tres compañías interesadas en sustituir a LUMA 5. Gobierno vuelve a cambiar su versión. Ahora director de OGP contradice a la gobernadora y dice hay dinero para el PAN. 6. Federales acusan por esquema corrupto en el Departamento de Hacienda- Empleados y empresarios 7. Buena noticia: farmacéutica Eli Lilly construirá nueva planta en PR 8. Otra buena noticia: la reserva federal baja la tasa de interés 9. Converso con Eric González de Gibaro de Puerto Rico y su nuevo espectáculoSee omnystudio.com/listener for privacy information.

Jim Cramer and David Faber explored what to make of earnings from three of the Magnificent 7 mega-caps: Meta shares tumbled and Microsoft's stock fell as AI spending increases overshadowed quarterly beats — while shares of Google parent Alphabet surged on better-than-expected results, fueled by strength in the cloud. Starbucks CEO Brian Niccol joined the program to discuss his company's results and turnaround plan. Eli Lilly CEO David Ricks spoke to Jim and David about his company's earnings and what's next for its Mounjaro weight loss drug. Also in focus: The meeting between Presidents Trump and Xi, Novo Nordisk-Pfizer bidding war, Chipotle plunges, Comcast's earnings message.Disclosure: Comcast is the parent company of NBCUniversal, which owns CNBC.Versant would become the new parent company of CNBC upon Comcast's planned spinoff of Versant.Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Plus: Nvidia unveils a new product that merges AI supercomputing with quantum. And the AI giant partners with Eli Lilly to build a supercomputer that could boost drug discovery. Julie Chang hosts. Correction: OpenAI's nonprofit parent owns a stake in its for-profit subsidiary, which has become a public-benefit corporation. An earlier version of this podcast incorrectly said OpenAI had become a for-profit company. (Corrected Oct. 28) Learn more about your ad choices. Visit megaphone.fm/adchoices